sulfonylurea and glp 1 combination GLP-1 receptor agonist versus DPP-4 inhibitor kidney and cardiovascular outcomes in clinical practice in type-2 diabetes image2.png

10.1016/S0076-6879(78)52032-6 8 ChiuA

The result should comply with the specification (0.2%)

any other condition which in the Investigators opinion may adversely affect the subjects ability to complete the study or its measures or which may pose significant risk to the subject

GLP-1 receptor agonists available in the UK include: Semaglutide (Ozempic, Wegovy, Rybelsus) - Ozempic and Rybelsus for diabetes, Wegovy for weight management Dulaglutide (Trulicity) Liraglutide (Victoza, Saxenda) - Victoza for diabetes, Saxenda for weight management Lixisenatide (Lyxumia) Exenatide (Byetta, Bydureon) - though usage has declined in recent years These medications are administered either as once-daily, once-weekly, or twice-daily subcutaneous injections, with one oral formulation (semaglutide) also available

To stimulate the insulin release, this second messenger activates mainly two pathways: protein kinase A (PKA) and the exchange protein directly activated by cAMP (Epac) (Kang, Leech, Chepurny, Coetzee & Holz, 2008